Gaudium IVF & Women Health IPO Details Issue Price, Date, News, Allotment Status, GMP Today, Link, Updates

Gaudium IVF and Women Health Limited IPO Strengths:

• It provides specialized fertility and reproductive healthcare services, offering a range of advanced assisted reproductive treatments including In vitro fertilization, intracytoplasmic sperm injection, intrauterine insemination, and ovulation induction. These solutions address diverse infertility challenges affecting both male and female patients. It also delivers comprehensive gynecological care, including diagnosis and management of conditions such as PCOD/PCOS and endometriosis, supporting reproductive health and long-term wellbeing.
• In terms of treatment volumes, it conducted 3,711 cycles in FY24 and 3,476 cycles in FY25, while 1,824 cycles were performed during H1FY26. In addition, the total number of outpatient department (OPD) visits stood at 7,208 in FY24, 8,145 in FY25, and 3,859 during H1FY26, reflecting steady patient engagement across periods.
• It delivers treatment using advanced medical technologies and state-of-the-art infrastructure. Its next-generation laboratories are equipped with INTEGRA Ti™ systems for precision ICSI procedures. It also utilizes advanced equipment for egg quality assessment, high-resolution ultrasound machines for accurate monitoring, and modern sterile operating environments designed to maintain the highest clinical and safety standards.
• The fertility rate in India has continued to decline in recent years, with 16 states and union territories reporting rates below 1.8, which is a cause for concern. It has strategically selected 19 locations with low fertility rates, ranging from 1.1 to 1.9, based on data from National Family Health Survey (NFHS‑5), 2019–21.
• The company has proposed to open 19 new centres across India in two phases. Phase 1 includes 10 centres in different states, including Delhi, Noida, and Pune, and is expected to be completed by FY27. Phase 2 will include 9 centres, including Chennai, Mumbai, and Kolkata, 8 are expected to be completed by FY28 and 1 by FY29.
• It recorded revenue from operations of ₹70.72 crore in FY25, representing a growth of 46.67% from ₹47.89 crore in FY24. It reported a PAT of ₹19.12 crore in FY25, reflecting growth of 85.39% from ₹10.31 crore in FY24. For the period ended September 2025, it reported revenue from operations of ₹49.49 crore and a PAT of ₹12.50 crore.
• The global IVF market, valued at USD 27.49 billion in 2024, is projected to reach USD 54.60 billion by 2034, reflecting a CAGR of 7.10%. In India, the IVF market is expanding rapidly, rising from USD 1.32 billion to USD 4.54 billion over the same period, growing at a CAGR of 13.13%.

Trade AnyTime AnyWhere With Elite Empower Mobile App

 

Gaudium IVF and Women Health Limited  IPO Risk Factors:

• It faces intense competition from listed domestic and international players, both directly and indirectly, such as Progyny Inc, Inspire IVF Public, Apollo Hospitals, Narayana Hrudayalaya, Fortis Healthcare, Max Healthcare, and Rainbow Children’s Medicare. These competitors may impact the company’s market share, revenue, and profitability.
• The industry in which the company operates is highly regulated. Any policy change that is not in the company’s favour may adversely impact its revenue and profitability.
• Failure to identify, understand, and adapt to rapidly evolving technological advancements in medical equipment and technology could adversely affect the company’s business prospects and financial performance.

Gaudium IVF and Women Health Limited  IPO Outlook:

Gaudium IVF and Women Health Limited is a specialized fertility care provider delivering assisted reproductive and women’s health services across India. It performed treatment cycles in 3,476 in FY25, and 1,824 in H1FY26. OPD visits rose to 8,145 in FY25 from 7,208 in FY24, reflecting consistent growth in patient engagement. It plans 19 new centres in two phases and currently operates 7 hubs and 28 spoke centres. It reported revenue from operations of ₹70.72 crore in FY25, reflecting a growth of 46.67% over FY24. PAT also increased by 85.39%, rising to ₹19.12 crore in FY25 from FY24. At the upper price band of ₹79, the issue is valued at a P/E of 25.35x on a pre-IPO basis and 30.06x on a post-IPO basis, based on FY25 earnings. There is no directly listed peer of the company, giving it a first-mover advantage. Considering the company’s valuation and the factors discussed above, we recommend applying to the issue for both listing gains and medium to long term investment horizon.

Gaudium IVF and Women Health Limited  IPO Financial Performance:

Gaudium IVF and Women Health Limited  IPO Shareholding Pattern:

Gaudium IVF & Women Health IPO FAQ:

Ans. The finalization of Basis of Allotment for Gaudium IVF IPO will be done on Wednesday, February 25, 2026, and the allotted shares will be credited to your demat account by Thu, Feb 26, 2026.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 214

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

• all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
• No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

• EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
• EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

2. Compensation

• EWL or its associates have not received any compensation from the subject company in the past twelve months;
• EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
• EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
• EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
• EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research

3. In respect of Public Appearances

• EWL or its associates have not received any compensation from the subject company in the past twelve months;
• The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL